Polaprezinc (Zinc L-carnosine) 用係胃炎到係一個相對地少研究的藥物。我只搵到中國同南韓有兩份paper係話佢對於
H. poly 引起的慢性胃炎有效。以我查到的資料而言,我會認為現時無確切證據說明其成效。
加拿大視佢為實驗性質
https://www.drugbank.ca/drugs/DB09221
澳洲視佢為輔助性藥物(complementary)
https://www.tga.gov.au/compositional-guideline/polaprezinc
係我手上幾個references都無講太多
MIMs Online: No Product Information (PI) 同 Consumer Medicines Information (CMI)
Australian Medicine Handbook: Not found
Micromedex:
Cochrane Library: 只有一個entry, 但係講radiotherapy
我於是用Engine查到36個entries
但近五年內只有2個,其中一個重要係老鼠實驗
Polaprezinc combined with clarithromycin-based triple therapy for
Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial:
77% 使用Triple therapy + 75mg Polaprezinc twice daily 的病患於14日內消除了H. poly
58.9% 使用Triple therapy 的病患於14日內消除了
H. poly
75mg Polaprezinc vs 150mg Polaprezinc 成效差唔多,但150mg 副作用機率係高2%
原文:
H. pylori:
Helicobacter pylori (H. pylori), one of the most globally prevalent pathogens, colonizes about 50% of the world’s population. It is transmitted from human to human and
causes chronic gastritis in all colonized subjects.
副作用機率:
The adverse event rate for Arm B (5.1%) was higher than for Arms A (2.8%) (P = 0.04) and C (1.9%) (P = 0.02).
篇文邊個都睇得。最好起碼睇下tables,唔明可以再問我。Table 3係講symptoms improvement, table 4 係adverse effects.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391070/
留意返其實個sample size唔大,所以會有adverse effects佢地underestimate/無發現
南韓:
https://www-sciencedirect-com.ezproxy.lib.monash.edu.au/science/article/pii/S0016510717311884?via%3Dihub
Drug-drug interaction:
https://www.drugbank.ca/drugs/DB09221/biointeractions